125 related articles for article (PubMed ID: 37748633)
21. Triamcinolone acetonide combined with aminoguanidine inhibits inflammation and oxidative stress, improves vascular endothelial and retinal function and reduces VEGF expression in diabetic retinopathy patients.
Xu K; Qian H; Zou M
Exp Ther Med; 2020 Apr; 19(4):2519-2526. PubMed ID: 32256730
[TBL] [Abstract][Full Text] [Related]
22. Triamcinolone and intraocular sustained-release delivery systems in diabetic retinopathy.
Yilmaz T; Cordero-Coma M; Lavaque AJ; Gallagher MJ; Padula WV
Curr Pharm Biotechnol; 2011 Mar; 12(3):337-46. PubMed ID: 20939800
[TBL] [Abstract][Full Text] [Related]
23. Posterior sub-Tenon's capsule injection of triamcinolone acetonide prevents panretinal photocoagulation-induced visual dysfunction in patients with severe diabetic retinopathy and good vision.
Shimura M; Yasuda K; Shiono T
Ophthalmology; 2006 Mar; 113(3):381-7. PubMed ID: 16458970
[TBL] [Abstract][Full Text] [Related]
24. Ocular delivery of sunitinib-loaded nanoparticles doped in tragacanthic acid hydrogel in treatment of diabetic retinopathy in rats.
Pirmardvand Chegini S; Varshosaz J; Dehghani A; Minaiyan M; Mirmohammad Sadeghi H
Drug Dev Ind Pharm; 2022 Jan; 48(1):29-39. PubMed ID: 35723593
[TBL] [Abstract][Full Text] [Related]
25. Episcleral drug film for better-targeted ocular drug delivery and controlled release using multilayered poly-ε-caprolactone (PCL).
Sun S; Li J; Li X; Lan B; Zhou S; Meng Y; Cheng L
Acta Biomater; 2016 Jun; 37():143-54. PubMed ID: 27071973
[TBL] [Abstract][Full Text] [Related]
26. Glycosylation-enhanced biocompatibility of the supramolecular hydrogel of an anti-inflammatory drug for topical suppression of inflammation.
Xiong T; Li X; Zhou Y; Song Q; Zhang R; Lei L; Li X
Acta Biomater; 2018 Jun; 73():275-284. PubMed ID: 29660509
[TBL] [Abstract][Full Text] [Related]
27. Diabetic Retinopathy Analysis-Effects of Nanoparticle-Based Triamcinolone.
Du S; Wang H; Jiang F; Wang Y
J Nanosci Nanotechnol; 2020 Oct; 20(10):6111-6115. PubMed ID: 32384959
[TBL] [Abstract][Full Text] [Related]
28. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
[TBL] [Abstract][Full Text] [Related]
29. Subconjunctival Delivery of p75NTR Antagonists Reduces the Inflammatory, Vascular, and Neurodegenerative Pathologies of Diabetic Retinopathy.
Galan A; Barcelona PF; Nedev H; Sarunic MV; Jian Y; Saragovi HU
Invest Ophthalmol Vis Sci; 2017 Jun; 58(7):2852-2862. PubMed ID: 28570737
[TBL] [Abstract][Full Text] [Related]
30. Triamcinolone acetonide modulates TGF‑β2‑induced angiogenic and tissue‑remodeling effects in cultured human retinal pigment epithelial cells.
Hsiao CC; Chang YC; Hsiao YT; Chen PH; Hsieh MC; Wu WC; Kao YH
Mol Med Rep; 2021 Nov; 24(5):. PubMed ID: 34523693
[TBL] [Abstract][Full Text] [Related]
31. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.
Becerra EM; Morescalchi F; Gandolfo F; Danzi P; Nascimbeni G; Arcidiacono B; Semeraro F
Curr Drug Targets; 2011 Feb; 12(2):149-72. PubMed ID: 20887246
[TBL] [Abstract][Full Text] [Related]
32. Triamcinolone acetonide-loaded lipid nanocapsules for ophthalmic applications.
Formica ML; Ullio Gamboa GV; Tártara LI; Luna JD; Benoit JP; Palma SD
Int J Pharm; 2020 Jan; 573():118795. PubMed ID: 31682964
[TBL] [Abstract][Full Text] [Related]
33. Topical instillation of triamcinolone acetonide-loaded emulsomes for posterior ocular delivery: statistical optimization and in vitro-in vivo studies.
Kapadia R; Parikh K; Jain M; Sawant K
Drug Deliv Transl Res; 2021 Jun; 11(3):984-999. PubMed ID: 32567039
[TBL] [Abstract][Full Text] [Related]
34. Novel hybrid lipid nanocapsules loaded with a therapeutic monoclonal antibody - Bevacizumab - and Triamcinolone acetonide for combined therapy in neovascular ocular pathologies.
Formica ML; Legeay S; Bejaud J; Montich GG; Ullio Gamboa GV; Benoit JP; Palma SD
Mater Sci Eng C Mater Biol Appl; 2021 Feb; 119():111398. PubMed ID: 33321575
[TBL] [Abstract][Full Text] [Related]
35. Microemulsion-based delivery of triamcinolone acetonide to posterior segment of eye using chitosan and butter oil as permeation enhancer: an in vitro and in vivo investigation.
Raval N; Khunt D; Misra M
J Microencapsul; 2018 Jan; 35(1):62-77. PubMed ID: 29307286
[TBL] [Abstract][Full Text] [Related]
36. Directing the nanoparticle formation by the combination with small molecular assembly and polymeric assembly for topical suppression of ocular inflammation.
Huang J; Yu X; Zhou Y; Zhang R; Song Q; Wang Q; Li X
Int J Pharm; 2018 Nov; 551(1-2):223-231. PubMed ID: 30213683
[TBL] [Abstract][Full Text] [Related]
37. Melt-Cast Films Significantly Enhance Triamcinolone Acetonide Delivery to the Deeper Ocular Tissues.
Tatke A; Dudhipala N; Janga KY; Soneta B; Avula B; Majumdar S
Pharmaceutics; 2019 Apr; 11(4):. PubMed ID: 30987011
[TBL] [Abstract][Full Text] [Related]
38. Suprachoroidal Injection of Triamcinolone Acetonide Suspension: Ocular Pharmacokinetics and Distribution in Rabbits Demonstrates High and Durable Levels in the Chorioretina.
Muya L; Kansara V; Cavet ME; Ciulla T
J Ocul Pharmacol Ther; 2022; 38(6):459-467. PubMed ID: 35404132
[No Abstract] [Full Text] [Related]
39. Improved release of triamcinolone acetonide from medicated soft contact lenses loaded with drug nanosuspensions.
García-Millán E; Quintáns-Carballo M; Otero-Espinar FJ
Int J Pharm; 2017 Jun; 525(1):226-236. PubMed ID: 28412447
[TBL] [Abstract][Full Text] [Related]
40. Vitreous pharmacokinetics and retinal safety of intravitreal preserved versus non-preserved triamcinolone acetonide in rabbit eyes.
Oliveira RC; Messias A; Siqueira RC; Bonini-Filho MA; Haddad A; Damico FM; Maia-Filho A; Crispim PT; Saliba JB; Ribeiro JA; Scott IU; Cunha AS; Jorge R
Curr Eye Res; 2012 Jan; 37(1):55-61. PubMed ID: 22029458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
